What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?

Xeris Biopharma (XERS) is identified as a strong momentum pick, boasting a Zacks Rank #2 (Buy) and a Momentum Style Score of B. The stock has significantly outperformed, rising 76.59% quarterly and 191.01% annually, well above S&P 500 returns. This robust price action is reinforced by recent positive earnings estimate revisions, with three estimates moving higher for both current and next fiscal years, improving the current year's consensus from -$0.07 to -$0.03. These combined factors position XERS as a compelling near-term investment.

Analysis

Xeris Biopharma (XERS) exhibits strong momentum characteristics, underpinned by both significant price outperformance and positive shifts in analyst earnings estimates. The stock's price has risen 191.01% over the last year and 76.59% over the past quarter, dramatically outpacing the S&P 500's gains of 21.49% and 8.64% over the same periods, respectively. This performance also exceeds its industry, with a monthly price change of 7.92% compared to the industry's 2.14%. This technical strength is supported by healthy trading volume, averaging 2,082,965 shares over the last 20 days. Fundamentally, the bullish case is reinforced by recent earnings estimate revisions. Over the past 60 days, three analysts have moved their full-year estimates higher with no downward revisions, causing the consensus estimate to improve from a loss of $0.07 to a loss of $0.03 per share. This positive revision trend also applies to the next fiscal year. This combination of factors culminates in a Zacks Rank of #2 (Buy) and a Momentum Style Score of B, signaling a strong near-term outlook based on the provided data.

Key Decisions for Investors

• Given the stock's significant outperformance and positive estimate revisions, investors with a momentum-oriented strategy should consider XERS as a potential long position to capitalize on its established upward trend.
• Investors should closely monitor the trend in earnings estimate revisions, as the recent upward adjustments are a core driver of the bullish thesis; any reversal could signal a weakening of momentum.
• While momentum is strong, the 191.01% annual gain means new investors are buying at elevated levels, making it crucial to watch for sustained high trading volume as confirmation of continued institutional interest.